Dina Chaya is a Partner with NeoMed Management, having been working with the firm since 2009. She has been investing in the private equity and venture capital healthcare industry in Europe and the US since 2001.
Previously at 3i plc in London and Index Ventures in Geneva, her recent investments including Oxular Ltd, TopiVert Ltd, Wilson Therapeutics AB (publ), EUSA Pharma, Inc., Endosense SA and Novexel SA.
Dina has been a board member of Endosense SA. She currently serves on the board of directors of Oxular Ltd, TopiVert Ltd and Wilson Therapeutics AB (publ).
Dina is a CFA charterholder and holds a Ph.D. degree in Molecular and Cellular Biology from Paris VI University, France. She carried out postdoctoral research at Brown University, Providence, US, and at the Fox Chase Cancer Centre, Philadelphia, US.